Dr. Heather Wakelee from Stanford University presents her view on the most promising emerging targeted therapies and pathways for treating lung cancer in the coming years.

[powerpress]

One of the more promising agents for advanced NSCLC in the last few years has been the oral Met inhibitor tivantinib, also known as ARQ-197.